股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國口腔產業集團控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08406 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | 本月底法定/ ...

Market Overview - The Hong Kong stock index opened high but closed lower, with the Hang Seng Index down 0.29% at 26,844.96 points, the Hang Seng Tech Index down 0.11% at 5,822.18 points, the National Enterprises Index down 0.5% at 9,220.81 points, and the Red Chip Index down 0.34% at 4,139.41 points [1] Company News - Tencent Holdings (00700.HK) repurchased 1.017 million shares for HKD 636 million at a price range of HKD 619-632 [2] - Xiaomi Group (01810.HK) repurchased 3.9 million shares for HKD 148 million at a price range of HKD 37.86-37.92 [3] - Six Fortune Group (00590.HK) reported a retail value increase of 26%, retail income increase of 17%, and same-store sales increase of 15% in Q3, exceeding expectations [3] - China Southern Airlines (01055.HK) reported a 11.89% increase in passenger capacity and a 19.28% increase in cargo capacity for December 2025 [6] Industry Insights - Tianfeng Securities noted that the Hong Kong stock market has a basis for short-term valuation recovery and sentiment improvement, but upward momentum may be constrained by high overseas interest rates [7] - The firm suggested a focus on technology and consumer sectors that are relatively undervalued [7] - According to Huatai Securities, the market is experiencing a shift towards a bullish sentiment, with historical data indicating a high probability of price increases following a period of panic [8] - Industry recommendations include prioritizing leading companies in the AI sector and exploring opportunities in insurance, banking, energy, and new consumption areas [8]

Core Viewpoint - The announcement indicates a strategic collaboration between China Dental Industry and Bio-Hui Biotechnology to enhance their business operations in the healthcare sector, particularly in the Greater Bay Area [1] Group 1: Strategic Collaboration - China Digital Health, a wholly-owned subsidiary of China Dental Industry, has signed a memorandum of understanding with Bio-Hui Biotechnology to establish a joint venture [1] - The joint venture aims to form qualified medical and biotechnology teams to promote clinical treatment services in hospitals within the Greater Bay Area [1] Group 2: Business Diversification - The board of directors believes that this memorandum marks a new phase for the group in entering the medical biotechnology field and provides opportunities for diversified business development [1] - Through this strategic partnership, the group aims to leverage its connections in the Greater Bay Area to broaden its revenue base and enhance overall competitiveness [1]

中国口腔产业(08406)发布公告，于2026年1月12日，本公司间接全资附属公司中国数字健康集团有限公 司与博惠生技股份有限公司订立谅解备忘录，以开展策略合作，以加强双方的业务。根据谅解备忘录， 双方拟成立合资公司，组成具有相关资质的医疗团队和生物科技团队，共同推动大湾区医院的临床治疗 业务。 博惠是台湾一家拥有先进细胞治疗技术、癌症免疫细胞治疗平台及临床实施能力的生物科技公司。 董事会认为，订立谅解备忘录标志着本集团进军医疗生物科技领域进入新阶段，并为本集团寻求多元化 业务发展的机会。透过与博惠的策略合作，本集团将能发挥其在大湾区的人脉关系，拓宽收入基础，提 升整体竞争力。鉴于上述理由及裨益，董事会认为订立谅解备忘录符合本公司及其股东的整体利益。 ...

Core Viewpoint - The announcement indicates a strategic collaboration between China Oral Industry and BioHui Biotechnology to enhance their business operations in the medical biotechnology sector, marking a new phase for the company [1] Group 1: Strategic Collaboration - China Digital Health Group, a wholly-owned subsidiary of China Oral Industry, has signed a memorandum of understanding with BioHui Biotechnology to establish a joint venture [1] - The collaboration aims to form qualified medical and biotechnology teams to promote clinical treatment services in the Greater Bay Area hospitals [1] Group 2: Company Growth and Diversification - The board believes that this memorandum signifies a new stage for the company’s entry into the medical biotechnology field and presents opportunities for diversified business development [1] - Through the strategic partnership with BioHui, the company aims to leverage its connections in the Greater Bay Area to broaden its revenue base and enhance overall competitiveness [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 China Oral Industry Group Holdings Limited 中國口腔產業集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號︰8406） 自願公告 諒解備忘錄 本 公 告 乃 中 國 口 腔 產 業 集 團 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 刊 發，旨 在 向 本 公 司 股 東（「股 東」）及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 的 最 新 資 料。 諒解備忘錄 本 公 司 董 事（「董 事」）董 事 會（「董事會」）欣 然 宣 布，於 二 零 二 六 年 一 月 十 二 日，本 公 司 間 接 全 資 附 屬 公 司 中 國 數 字 健 康 集 團 有 限 公 司（「中國數字健康」）與 博 惠 生 技 股 份 有 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國口腔產業集團控股有限公司 呈交日期: 2026年1月5日 本月底法定/註冊股本總額： HKD 50,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08406 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,368,000,000 | | 0 | | 1,368,000,000 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 1,36 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國口腔產業集團控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08406 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | 本月底法 ...

Core Viewpoint - The latest data from the Hong Kong Stock Exchange indicates that shareholders of China Oral Industry (08406) have deposited stocks worth HKD 23.94 million into Huazhang Securities Hong Kong Brokerage, accounting for 16.67% of the total [1] Financial Performance - For the mid-year results of 2025, China Oral Industry reported revenue of approximately CNY 109 million, representing a year-on-year decrease of 12.35% [1] - The net profit for the same period was CNY 4.069 million, showing a significant year-on-year increase of 362% [1] - Earnings per share were reported at 0.3 cents [1]

Group 1 - The core point of the article highlights the recent stock deposit by shareholders of China Oral Industry (08406) into Huazhang Securities Hong Kong, with a market value of HKD 23.94 million, representing 16.67% of the total [1] - For the mid-year results of 2025, China Oral Industry reported revenue of approximately HKD 109 million, reflecting a year-on-year decrease of 12.35% [1] - The net profit for the same period was HKD 4.069 million, showing a significant year-on-year increase of 362% [1] - Earnings per share were reported at 0.3 cents [1]